Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

OBJECTIVES: The efficacy of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, has not previously been evaluated in a population consisting exclusively of patients with early rheumatoid arthritis (RA). METHODS: In a double-blind randomised controlled trial (FUNCTION), 1162 methotrexate (MTX...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Rheum Dis
Hlavní autoři: Burmester, Gerd R, Rigby, William F, van Vollenhoven, Ronald F, Kay, Jonathan, Rubbert-Roth, Andrea, Kelman, Ariella, Dimonaco, Sophie, Mitchell, Nina
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2016
Témata:
Clinical and Epidemiological Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893095/
https://ncbi.nlm.nih.gov/pubmed/26511996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-207628
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky